Loading stock data…
Zymeworks Inc. (ZYME)
$28.11-1.08 (-3.70%)
Market ClosedLast close Sep 8
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zymeworks Inc. in the Healthcare sector is trading at $28.11 with a market capitalization of $2.1B. Wall Street consensus targets $41.75 (12 analysts), implying a +48.5% move over the next 12 months. The stock is currently near its 52-week high of $31.34, remaining 12.5% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +48.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.59M↑ | $2.41M↓ | $2.52M↓ | $27.61M↓ | $48.73M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$42.15M↑ | -$47.15M↓ | -$44.12M↓ | -$22.06M↓ | -$623,000 |
| Net Income | -$45.02M↓ | -$44.16M↓ | -$41.21M↓ | -$19.60M↓ | $2.32M |
Peer Comparison
JNJUNHPFE
Fundamentals
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a s...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.09B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-186.63%
Volume
Today's trading volume
442,036
Recent News
JAZZ Rises on Updated OS Results From Gastric Cancer Study
Jazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma.
Zymeworks (ZYME), What Is Behind The Renewed Attention?
Why Zymeworks Stock Is Back in Focus After FDA Approval Zymeworks (ZYME) moved into the spotlight after the FDA approved zanidatamab for first line HER2 positive gastroesophageal adenocarcinoma, putting fresh attention on what this decision might imply for future revenue potential. Against this backdrop, Zymeworks has seen momentum build, with a 30 day share price return of 28.31% and a 90 day gain of 15.44%. The 1 year total shareholder return of 95.49% and very large 3 year total...
Is Zymeworks (ZYME) Stock Fully Priced After Its 301% Run?
Zymeworks stock has delivered very strong returns over the past three years, yet the broader valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Recent gains and optimism around its HER2-targeting therapy are now being weighed against signals that point to limited valuation cushion at today’s levels. Zymeworks has returned about 301% over the past three years, which puts extra focus on whether recent gains already reflect much of the good...
Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens
On Tuesday, the U.S. Food and Drug Administration (FDA) approved Jazz Pharmaceuticals plc’s two Ziihera-containing combination regimens as first-line treatments for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. Zanidatamab is being developed in multiple clinical trials as...
SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?
SJM raised its annual outlook following a quarterly earnings beat, while ZYME gained on price-target hikes tied to Ziihera’s FDA approval.